PRESS RELEASES

PRESS RELEASES

April 8, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Apr. 8, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Jimmy Bornheimer , Vice President of Finance, and
March 19, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 19, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported financial results for the fourth quarter and full year ended December 31,
March 13, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 13, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin’s proprietary demineralization technology, OsteoSTX are flexible cortical DBM
March 10, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 10, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, announced the closing of an additional $4 million financing from OrbiMed.
February 4, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Feb. 4, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CEO, Dan Goldberger , and CFO, John Gandolfo , will present at the
January 23, 2014
Fourth Quarter Revenue in the range of $8.15 million to $8.28 million , an increase of 4% sequentially, and 1.5% over the same period last year. Fourth Quarter Biologics Revenue in the range of $8.02 million to $8.07 million , up 5.0% sequentially and 4.5% over the same period last year.